SPEU - Europe now higher by more than 4% after positive Pfizer vaccine trial data

The first interim efficacy analysis of the large-scale Phase 2/3 clinical trial evaluating Pfizer and BioNTech's COVID-19 vaccine candidate, BNT162b2, showed it to be more than 90% effective seven days after the second dose in preventing infection in participants with no evidence of prior SARS-CoV-2 infection.With most of the Continent back in at least partial lockdown, the news is of quite particular importance. The Stoxx 600 (FEZ) is now higher by 4.1%, led by Spain's (EWP) 7.5% advance. Germany (EWG) is up 5.7%, France (EWQ) 7%, and Italy (EWI) 7.4%. The U.K. (EWU) is ahead 4.9%.Related ETFs: [[VGK]], [[FEZ]], [[HEDJ]], [[EZU]], [[IEV]], [[IEUR]], [[EURL]], [[EPV]], [[SPEU]], [[DBEU]], [[EEA]], [[HEZU]]

For further details see:

Europe now higher by more than 4% after positive Pfizer vaccine trial data